中国临床药理学与治疗学2018，Vol.23Issue(1)：110-115,6.DOI:10.12092/j.issn.1009-2501.2018.01.021
我院区2016年利奈唑胺临床应用合理性评价
Evaluation of clinical rationality of linezolid in our hospital in 2016
徐佳 1黄琪 1杨志玲1
作者信息
- 1. 湖南省人民医院(湖南师范大学第一附属医院)药学二部,长沙410016,湖南
- 折叠
摘要
Abstract
AIM:To evaluate the clinical rationality,efficacy and safety of linezolid in our hospital in 2016 and to provide reference for its clinical application.METHODS:A retrospective study was conducted using the medical history data of patients treated with linezolid in 2016.The questionnaire was designed to compile statistics of rational use rate,to analyze the causes of irrational use,and to calculate the clinical cure rate,pathogen clearance rate and comprehensive cure rate,as well as to monitor the red blood cell,hemoglobin and platelet decline after treatment of linezolid.RESULTS:The rational use rate of linezolid was 48.1％,the irrational reasons are mainly that the indication was unreasonable and the course of treatment was unreasonable.The clinical cure rate was 40.4％,the pathogen clearance rate was 42.3％,and the comprehensive cure rate was 56.4％.The incidence of myelosuppression was 21.2％ in patients whose average age was (81.4 ± 8.7) years old,and the average course of treatment was (13.6 ± 5.6) days.CONCLUSION:The rate of clinical rational use of linezolid needs to be improved in our hospital.The correct indication and course of treatment will improve the rational rate to a great extent.And the comprehensive curative effect is acceptable.But special attention should be paid to the occurrence of myelosuppression for the elderly patients.关键词
利奈唑胺/耐甲氧西林金葡菌(MRSA)/血小板减少Key words
linezolid/methicillin resistant Staphylococcus aureus (MRSA)/thrombocytopenia分类
医药卫生引用本文复制引用
徐佳,黄琪,杨志玲..我院区2016年利奈唑胺临床应用合理性评价[J].中国临床药理学与治疗学,2018,23(1):110-115,6.
